Weekly pill could slow aging: early trial launches

NCT ID NCT05949658

Recruiting now Disease control Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This Phase 1 trial tests two drugs, sirolimus and everolimus, given once a week to healthy adults aged 55-89. The goal is to find the safest dose that might slow the aging process. Participants take the drug for 6 weeks and are monitored for side effects and drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

sirolimus and everolimus (weekly oral doses)

What this could lead to

If successful, this could point toward a safe, weekly pill that slows the aging process and extends healthy lifespan.

What could go wrong

This is a very early Phase 1 trial with only 72 healthy participants over 17 weeks. The drugs may cause side effects or fail to show meaningful anti-aging effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGING

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

University of Wisconsin
RECRUITING

Madison, Wisconsin, 53705, United States

Contact